<DOC>
	<DOCNO>NCT00726687</DOCNO>
	<brief_summary>This phase 1b study Indibulin combination Capecitabine advance solid tumor .</brief_summary>
	<brief_title>Phase 1b Study Indibulin Combination With Capecitabine Advanced Solid Tumors</brief_title>
	<detailed_description>The primary objective trial determine maximum tolerate dose ( MTD ) optimal dose schedule indibulin combination capecitabine subject diagnose advanced solid tumor . Secondary objective include determination dose-limiting toxicity ( DLT ) , safety tolerability , preliminary activity combination . In addition , biological activity indibulin combination capecitabine evaluate . Single arm , open label , Phase Ib , dose-escalation study indibulin combination capecitabine subject advance histologically confirm , solid tumor standard therapy exist treatment capecitabine consider medically acceptable . 3 subject treat dose level . When DLT occur 2 6 few subject , MAD reach dose reduce previous dose level , consider MTD .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects advance , histologically confirm solid tumor treatment capecitabine consider medically acceptable 2 . ≥18 year age 3 . ECOG performance score ≤2 ( see Appendix 2 ) 4 . Eligible subject MUST least one measurable lesion define RECIST guideline ( see Appendix 3 ) . Measurable lesion MUST NOT previously irradiate field injected biological agent . 5 . Lifeexpectancy ≥12 week 6 . No 2 prior chemotherapy regimens metastatic disease 7 . Subjects prophylactic anticoagulation ( i.e. , lowdose warfarin ) eligible provide coagulation parameter level follow : prothrombin time ( INR prothrombin time ) &lt; 1.1× institutional ULN 8 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct &lt; 2 week prior Study Day 1 : Creatinine ≤1.5 × upper limit normal ( ULN ) OR calculate creatinine clearance ≥1.50 cc/min ( See Appendix 6 calculation method ) Total bilirubin ≤1.5×ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤2.5×ULN ( &lt; 5×ULN patient present liver involvement ) White blood cell count ≥3.0×109/L Absolute neutrophil count ( ANC ) ≥1.5×109/L Platelets ≥100×109/L Hemoglobin ≥10 g/dL 9 . Written inform consent compliance ZIOPHARM policy Institutional Review Board ( IRB ) jurisdiction site 10 . Ability willingness undergo multiple venous puncture serum PK sample 11 . For second phase trial ( expand cohort 10 ) , capecitabinenaïve subject include ; prior therapy 5FU allow 12 . Each man woman childbearing potential must agree use reliable method contraception study 3 month follow last dose study drug Exclusion Criteria 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month ( see Appendix 4 ) 2 . Severe renal impairment ( creatinine clearance 30 mL/min ) 3 . Known dihydropyrimidine dehydrogenase deficiency ( DPD ) 4 . Any evidence bleeding diathesis coagulopathy 5. International normalized ration ( INR ) &gt; 1.5 , unless subject fulldose warfarin 6 . Subjects fulldose anticoagulant ( e.g. , warfarin ) eligible provide follow criterion meet : The subject must inrange INR ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecularweight heparin The subject must active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) 7 . Pregnancy and/or lactation . To enrol , woman childbearing potential must negative pregnancy test , repeat end study . 8 . Uncontrolled systemic infection ( documented microbiological study ) 9 . Anticancer chemotherapy immunotherapy within 4 week study entry time study investigational drug therapy outside trial within 4 week study entry 10 . Mitomycin C nitrosureas give within 6 week study entry . 11 . Radiotherapy within 3 week study entry time study . For target lesion radiate within 3 month study entry , lesion document progression post radiation allow . 12 . Surgery within 4 week start study drug dosing , exclude tumor biopsy pharmacodynamic parameter 13 . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer 14 . Substance abuse medical , psychological social condition may interfere subject 's participation study evaluation study result 15 . Any condition unstable could jeopardize safety subject his/her compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Indibulin</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>